MX2021007932A - Molecula oligomerica de acido nucleico y uso de esta. - Google Patents

Molecula oligomerica de acido nucleico y uso de esta.

Info

Publication number
MX2021007932A
MX2021007932A MX2021007932A MX2021007932A MX2021007932A MX 2021007932 A MX2021007932 A MX 2021007932A MX 2021007932 A MX2021007932 A MX 2021007932A MX 2021007932 A MX2021007932 A MX 2021007932A MX 2021007932 A MX2021007932 A MX 2021007932A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecule
small
activating
application
Prior art date
Application number
MX2021007932A
Other languages
English (en)
Inventor
Longcheng Li
Moorim Kang
Original Assignee
Ractigen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ractigen Therapeutics filed Critical Ractigen Therapeutics
Publication of MX2021007932A publication Critical patent/MX2021007932A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0318Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/11Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una molécula de ácido nucleico activador pequeño para tratar la atrofia muscular espinal y el uso de esta; la molécula de ácido nucleico activador pequeño comprende una cadena de ácido nucleico sentido y una cadena de ácido nucleico antisentido, en donde la cadena de ácido nucleico sentido y la cadena de ácido nucleico antisentido son independientemente una cadena oligonucleotídica de 16 a 35 nucleótidos de longitud, en la que una cadena nucleotídica tiene al menos 75 % de homología o complementariedad de bases con respecto a una diana seleccionada de una región promotora de un gen diana SMN2; la presente invención también se relaciona con una composición farmacéutica que comprende la molécula de ácido nucleico activador pequeño descrita en la presente y, opcionalmente, un transportador farmacéuticamente aceptable, y un método para aumentar la expresión de un gen diana en células y métodos para tratar una enfermedad inducida por la expresión insuficiente de un gen diana con la molécula de ácido nucleico activador pequeño o la composición farmacéutica que comprende la molécula de ácido nucleico activador pequeño descrita en la presente.
MX2021007932A 2018-12-29 2019-12-27 Molecula oligomerica de acido nucleico y uso de esta. MX2021007932A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811634268 2018-12-29
PCT/CN2019/129025 WO2020135677A1 (zh) 2018-12-29 2019-12-27 寡聚核酸分子及其应用

Publications (1)

Publication Number Publication Date
MX2021007932A true MX2021007932A (es) 2021-08-16

Family

ID=71125998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007932A MX2021007932A (es) 2018-12-29 2019-12-27 Molecula oligomerica de acido nucleico y uso de esta.

Country Status (13)

Country Link
US (1) US20220064642A1 (es)
EP (1) EP3904517A4 (es)
JP (1) JP2022515881A (es)
KR (1) KR20210110310A (es)
CN (1) CN112996913B (es)
AU (1) AU2019414608A1 (es)
BR (1) BR112021012422A2 (es)
CA (1) CA3120534A1 (es)
IL (1) IL284333A (es)
MX (1) MX2021007932A (es)
PE (1) PE20212248A1 (es)
SG (1) SG11202106327QA (es)
WO (1) WO2020135677A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189091A1 (en) * 2020-07-31 2023-06-07 Ractigen Therapeutics Combinatory treatment of sma with sarna and mrna modulators
CN112779252B (zh) * 2020-12-31 2023-05-26 首都儿科研究所 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
KR20230154026A (ko) * 2021-02-08 2023-11-07 락티젠 세러퓨틱스 다가 올리고뉴클레오티드 작용제 및 이의 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005042A2 (en) * 2004-06-30 2006-01-12 Cemines, Inc. Methods and compositions for the diagnosis,prognosis,and treatment of cancer
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
CN1904900A (zh) * 2005-07-28 2007-01-31 中国科学院生物物理研究所 人类的内源性siRNA序列及其应用和筛选方法
US20080187512A1 (en) * 2007-02-07 2008-08-07 Academia Sinica Treatment for spinal muscular atrophy
AU2013262663A1 (en) * 2012-05-16 2015-01-22 The General Hospital Corporation D/B/A Massachusetts General Hospital Compositions and methods for modulating gene expression
WO2015051283A1 (en) * 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN104630219B (zh) * 2013-11-15 2019-05-07 中美瑞康核酸技术(南通)研究院有限公司 抑癌基因IRX1的saRNA分子及其组合物和其应用
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用
WO2016170348A2 (en) * 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use
EP3368671A1 (en) * 2015-10-26 2018-09-05 Translate Bio Ma, Inc. Methods and compositions for increasing smn expression
WO2017087486A1 (en) * 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
US9669109B1 (en) * 2015-11-24 2017-06-06 Universita Di Ferrara Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
EP3471779A4 (en) * 2016-06-16 2020-07-08 Ionis Pharmaceuticals, Inc. COMBINATIONS FOR MODULATING THE SMN EXPRESSION
CA3034385A1 (en) * 2016-07-21 2018-01-25 The General Hospital Corporation Extracellular mrna markers of muscular dystrophies in human urine

Also Published As

Publication number Publication date
PE20212248A1 (es) 2021-11-24
SG11202106327QA (en) 2021-07-29
CN112996913B (zh) 2022-01-04
US20220064642A1 (en) 2022-03-03
EP3904517A4 (en) 2022-12-28
CN112996913A (zh) 2021-06-18
EP3904517A1 (en) 2021-11-03
KR20210110310A (ko) 2021-09-07
IL284333A (en) 2021-08-31
JP2022515881A (ja) 2022-02-22
AU2019414608A1 (en) 2021-07-22
BR112021012422A2 (pt) 2021-10-26
WO2020135677A1 (zh) 2020-07-02
CA3120534A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
MX2021007932A (es) Molecula oligomerica de acido nucleico y uso de esta.
ES2558962T3 (es) Polinucleótido bicatenario
MX2023005326A (es) Composiciones de oligonucleótidos y métodos de las mismas.
WO2009142822A3 (en) 2-f modified rna interference agents
MX2021012126A (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
SG10201903290YA (en) Modified double-stranded rna agents
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
PH12021551122A1 (en) Method for treating muscular dystrophy by targeting utrophin gene
BRPI0811170B8 (pt) oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
ATE460481T1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
WO2008116860A3 (en) Dsrna compositions and methods for treating hpv infections
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
DE60325016D1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
MX2018012695A (es) Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
AR123420A1 (es) Inhibidores de dux4 y métodos de uso de estos
JP2007530431A5 (es)
MX2021014478A (es) Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
US11072795B2 (en) Antisense oligonucleotides
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
HK1159988A1 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene